Overview


According to FutureWise analysis the market for antisense and rnai therapeutics in 2023 is US$ 1.58 billion, and is expected to reach US$ 2.87 billion by 2031 at a CAGR of 7.7%.

Antisense and RNA interference (RNAi) therapeutics represent groundbreaking approaches in molecular medicine. These therapies target genetic disorders and diseases at the molecular level, offering promising avenues for treatment. Antisense therapy involves synthetic molecules, typically short single-stranded nucleotides, designed to bind with specific messenger RNA (mRNA) molecules. By doing so, they hinder mRNA translation into proteins, effectively modulating gene expression. This approach has shown great potential in treating various diseases, including genetic disorders, viral infections, and some types of cancer. RNA interference (RNAi), on the other hand, leverages the cell's natural processes for regulating gene expression. It introduces small RNA molecules, such as (siRNA) small interfering RNA or short hairpin RNA (shRNA), which guide the degradation of target mRNA molecules. This leads to a reduction in the production of the corresponding proteins. RNAi has demonstrated immense therapeutic promise for conditions driven by overactive or malfunctioning genes.

The market for antisense and RNAi therapeutics has been steadily growing, driven by several factors. Technological advancements in nucleic acid chemistry and delivery system improvements have substantially enhanced the efficacy and specificity of these therapies.

FutureWise Market Research has published a report that provides an insightful analysis of Antisense and RNAi Therapeutics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antisense and RNAi Therapeutics Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • GlaxoSmithKline Plc
  • Sanofi-Genzyme
  • Alnylam Pharmaceuticals
  • Marina Biosciences
  • Benitec Biopharma
  • Olix Pharmaceuticals
  • Ionis Pharmaceuticals
  • Acuitas Therapeutics
  • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
  • Silence Therapeutics Plc
  • Enzon Pharmaceuticals Inc
  • Antisense Therapeutics Ltd.
  • Bio-Path Holdings Inc.
  • Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)
  • Gene Signal
  • Gradalis
  • iCo Therapeutics
  • Lorus Therapeutics (Aptose Biosciences)
  • miRagen Therapeutics
  • Mirna Therapeutics Inc
  • OncoGeneX Pharmaceuticals
  • Quark Pharmaceuticals
  • Rexahn Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Technology

  • RNA Interference
    • siRNA
    • miRNA
  • Antisense RNA

By Application

  • Oncology
  • Cardiovascular Diseases (CVDs)
  • Respiratory Disorders
  • Renal Diseases
  • Neurodegenerative Disorders
  • Genetic Disorders
  • Infectious Diseases

By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intra-dermal Injections
  • Intraperitoneal Injections
  • Topical Delivery
  • Other Delivery Methods

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antisense and RNAi Therapeutics Market By Technology, By Application, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antisense and RNAi Therapeutics Market Variables, Trends and Scope
    •   1. Market LineProducts Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antisense and RNAi Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antisense and RNAi Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antisense and RNAi Therapeutics Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. RNA Interference
         1.1. siRNA
         1.2. miRNA
        2. Antisense RNA

  • 8.   Global Antisense and RNAi Therapeutics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Cardiovascular Diseases (CVDs)
        3. Respiratory Disorders
        4. Renal Diseases
        5. Neurodegenerative Disorders
        6. Genetic Disorders
        7. Infectious Diseases

  • 9.   Global Antisense and RNAi Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pulmonary Delivery
        2. Intravenous Injections
        3. Intra-dermal Injections
        4. Intraperitoneal Injections
        5. Topical Delivery
        6. Other Delivery Methods

  • 10.   North America Antisense and RNAi Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antisense and RNAi Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antisense and RNAi Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antisense and RNAi Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline Plc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi-Genzyme
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Alnylam Pharmaceuticals
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Marina Biosciences
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Benitec Biopharma
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Olix Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ionis Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Acuitas Therapeutics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Silence Therapeutics Plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Enzon Pharmaceuticals Inc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Antisense Therapeutics Ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bio-Path Holdings Inc.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.)
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Gene Signal
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Gradalis
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. iCo Therapeutics
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Lorus Therapeutics (Aptose Biosciences)
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. miRagen Therapeutics
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Mirna Therapeutics Inc
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. OncoGeneX Pharmaceuticals
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Quark Pharmaceuticals
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Rexahn Pharmaceuticals
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Antisense Oligonucleotides Market

Read More

CNS Specific Antisense Oligonucleotide Market

Read More
Partner

Our Clients